Research programme: Liposomal cytotoxic compounds - GP Pharm
Latest Information Update: 22 Jan 2016
At a glance
- Originator GP Pharm
- Class Alkaloids; Anthracyclines; Antineoplastics; Camptothecins; Deoxyribonucleosides; Doxorubicins; Pyrimidine nucleosides; Small molecules; Taxanes
- Mechanism of Action DNA intercalators; DNA synthesis inhibitors; Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation promoters; Type II DNA topoisomerase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 22 Jan 2016 Preclinical trials in Cancer in Spain (parenteral) before January 2016